BioCentury
ARTICLE | Clinical News

FDA: No new safety concerns for Acadia's PD psychosis drug

September 21, 2018 4:25 PM UTC

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) rose $4.01 (27%) to $19.11 on Sept. 20, adding more than $500 million in market cap, after an FDA safety review of the company's Nuplazid pimavanserin found postmarketing safety data were consistent with the label's safety profile.

The small molecule serotonin (5-HT2A) receptor inverse agonist is approved to treat Parkinson's disease psychosis (PDP)...

BCIQ Company Profiles

Acadia Pharmaceuticals Inc.